Are you Dr. Sneller?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
National Institutes Of Health
10 Center Drive Msc 1876
Bethesda, MD 20892Phone+1 301-496-0491Fax+1 301-496-0491
Summary
- Dr. Michael Sneller, MD is an infectious disease specialist in Bethesda, Maryland. He is currently licensed to practice medicine in Maryland and North Carolina.
Education & Training
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1983 - 1986
Duke University HospitalResidency, Internal Medicine, 1980 - 1983
University of Kansas School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 1985 - 2025
NC State Medical License 1982 - 1998- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection Start of enrollment: 2008 Nov 20
- Oxford Signature vs. Conventional Global Study Start of enrollment: 2012 Sep 01
- Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up Start of enrollment: 2017 Dec 02
- Join now to see all
Publications & Presentations
PubMed
- 242 citationsTreatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.Gary S. Hoffman, Randi Y. Leavitt, Gail S. Kerr, Menachem Rottem, Michael C. Sneller
Arthritis and Rheumatism. 1994-12-01 - 350 citationsA multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.Gary S. Hoffman, Maria C. Cid, David B. Hellmann, Loïc Guillevin, John H. Stone
Arthritis and Rheumatism. 2002-05-01 - 21 citationsKinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.Michael C. Sneller, Erin D Huiting, Katherine E Clarridge, Catherine Seamon, Jana Blazkova
The Journal of Infectious Diseases. 2020-10-13
Press Mentions
We Might Have Long Covid All WrongDecember 8th, 2022- New Research Finds That Omicron Longs Nearly Half the Risk of COVID as DeltaJune 17th, 2022
- Omicron Poses About Half the Risk of Long COVID as Delta, New Research FindsJune 17th, 2022
- Join now to see all
Grant Support
- Clinical, Immunopathogenic And Therapeutic Studies Of SyNational Institute Of Allergy And Infectious Diseases2002–2004
- Clinical/Immunopathogenic/Therapeutic Studies:VasculitisNational Institute Of Allergy And Infectious Diseases2001
- Clinical, Immunopathogenic And Therapeutic Studies Of Systemic VasculitisNational Institute Of Allergy And Infectious Diseases2000
- Clinical, Immunopathogenic And Therapeutic Studies Of Systemic Vasculitis And ..National Institute Of Allergy And Infectious Diseases1998–1999
- Clinical, Immunopathogenic, Therapeutic Studies Of Vasculitis And Other DiseasesNational Institute Of Allergy And Infectious Diseases1993–1997
- Studies Of Primary Immunodeficiency DiseasesNational Institute Of Allergy And Infectious Diseases1990–1992
